All News

The first patient with locally advanced rectal cancer has been enrolled in the FORTRESS study which is evaluating the investigative immunotherapy NG-350A.

Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for further treatment expansion.

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on to final analysis.

The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a form of brain cancer.

There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.

Adolescent and young adult patients with cancer face delayed diagnoses, financial hardships and gaps in specialized care, creating a need for tailored support.

Eleven years post diagnosis and issues related to breast cancer still frustrate me.

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.

A new comprehensive hereditary cancer solution offers genetic counseling and multigene panels to enhance early detection of disease's like brain cancer.

Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal cancers.

As a caregiver, I learned that CyberKnife radiation for metastatic prostate cancer comes with psychological and physical challenges.

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the global phase 3 MIRACLE trial.

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to COMPANION-002 study results.

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.

CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being reassured everything is fine.

A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ovarian cancer.

I’ve spent 14 years navigating recovery, mental health challenges and giving back to the cancer community through patient mentorship.

The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

Dr. Regina Hampton discusses key factors contributing to this disparity, and how healthcare systems can address these challenges.

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in muscle invasive bladder cancer.

I reflect on how cancer has brought out resilience and support in others, even as I struggled with my own battle, and wish others strength in their journeys.

CURE spoke with Leslie Waltke about the importance of physical therapy during a cancer journey.